RZLT

Rezolute Inc.

NASDAQ

Add Alert

RZLT

Rezolute Inc.

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Newer

alexindef

02/08/13 11:29 AM

Post #9

Re: #8: @Renee - FMYY changed to ANTB:

Thank you, Renee

I expect to see AntriaBio's story unfold in a few weeks

Renee

02/07/13 5:32 PM

Post #8

Re: #7: @alexindef - AntriaBio Completes Merger and Elects Board of Directors

FMYY changed to ANTB:

http://www.otcbb.com/asp/dailylist_detail.asp?d=02/07/2013&mkt_ctg=OTCBB

alexindef

02/07/13 9:53 AM

Post #7

AntriaBio Completes Merger and Elects Board of Directors

MENLO PARK, CA--(Marketwire - Feb 6, 2013) - AntriaBio Delaware, Inc. f/k/a AntriaBio, Inc. ("AntriaBio Delaware") ( OTCQB : FMYY ), a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the closing of its planned and previously announced merger with AntriaBio, Inc. f/k/a Fits My Style Inc., a Nevada corporation. Following the merger, the company is now listed as AntriaBio, Inc. ("AntriaBio"), and trading on the OTC Bulletin Board and the OTCQB under the symbol "FMYY." In connection with the merger, AntriaBio appointed three new directors.

As part of the terms of the merger, AntriaBio Delaware's stockholders received 35,284,000 newly issued shares of AntriaBio common stock, which constitutes approximately 88% of the issued and outstanding common stock of AntriaBio. Details of the share exchange transaction can be found in our current report on Form 8-K filed with the United States Securities and Exchange Commission.
Following the reverse merger, the directors of AntriaBio will include AntriaBio Delaware President and CEO Nevan Elam, AntriaBio Delaware Executive Chairman Steve R. Howe, Hoyoung Huh, M.D., Ph.D, and Nickolay V. Kukekov, Ph.D. Details on the appointments can be found on the Information Statement filed with the United States Securities and Exchange Commission on January 14, 2013.
Upon the closing of the asset purchase with PR Pharmaceuticals, Inc., AntriaBio's lead product candidate is AB101. AB101 is a once-a-week injectable basal insulin in preclinical development. AB101 is administered by subcutaneous injection and targets patients with Type 1 and Type 2 diabetes who require basal insulin for the control of hyperglycemia. The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week.

About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA-approved pharmaceutical agents with our proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes.
For more information visit: www.antriabio.com

alexindef

01/23/13 12:42 PM

Post #6

http://antriabio.com/portfolio/team/

Pay attention to this guy:

Nickolay V. Kukekov, Ph.D.

Nickolay Kukekov is a Managing Director at Highline Research Advisors. Prior to forming Highline Research Advisors, a division of John Thomas Financial, Dr. Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research and, prior to that, was a Co-founder of the Healthcare Investment Banking group at Gilford Securities. Prior to joining Gilford, Dr. Kukekov was a Managing Director at Paramount BioCapital, where he ran the advisory, M&A and capital raising services for in-house private and public portfolio companies. Before that, he was a senior healthcare investment banker at Rodman & Renshaw. His scientific background includes a bachelor degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder and a Ph.D. in Neuroscience from Columbia University, College of Physicians and Surgeons in New York. Dr. Kukekov holds a number of research scholarship awards and peer review publications.

He was the financial arm behind MRIC at its run in July last year.

alexindef

01/23/13 12:38 PM

Post #5

http://antriabio.com/careers/

Clinical Development Expert

Clinical Development expert with analytical scientific mind who will be responsible for clinical development strategy, clinical trial oversight and management, and support of clinical interactions with regulatory agencies and KOLs. This individual will also participate in identification of, and developing the long-range strategic plans for, AntriaBio pipeline products. The Director/Senior Director will lead the design, implementation, monitoring, analysis, and reporting of clinical studies and overall clinical programs supporting company pipeline products.

alexindef

01/23/13 12:37 PM

Post #4

Re: #3: @alexindef - 1.95 x 2.5

$2.25 x $2.45

Liquidity will come soon...

alexindef

01/22/13 12:29 PM

Post #3

1.95 x 2.5

liquidity will be coming soon; going to trade as MRIC in July...

alexindef

01/20/13 7:56 PM

Post #2

Symbol request sent to stockcharts.com

alexindef

01/20/13 7:54 PM

Post #1

IBox with a basic info has been created. More to follow...

Newer

Rezolute Inc. (RZLT)

Followers	17	Posters	46
Posts (Today)	0	Posts (Total)	419
Created	01/20/13	Type	Free
Moderators

AntriaBio, Inc.
890 Santa Cruz Avenue
Menlo Park, CA 94025
P: (650) 223-5441
info@antriabio.com

Reverse Merger

Jan 7, 2013 - AntriaBio, Inc., a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the acquisition of the significant assets of PR Pharmaceuticals, Inc. and its intention to become a publicly traded company through a merger.

"AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery," said Nevan Elam, AntriaBio's President and CEO. "AB101 may offer significant advantages over basal insulin products sold by Sanofi-Aventis and Novo Nordisk, which together sell more than $7B annually."

AntriaBio's lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.

The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level which supplements the effects of endogenous and exogenous insulin and complements the effects of orally administered hypoglycemic agents. AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery.

AB101's long duration of action is the result of our ability to PEGylate insulin and then encapsulate it into poly-lactic, poly-glycolic (PLGA) microspheres. Currently available PEGylated biomolecules typically use large molecular weight PEG chains to decrease clearance and therefore reduce injection frequency. However, we use a very small molecular weight PEG for AB101 to modify the solubility of insulin and permit encapsulation of the drug into a biodegradable polymer.

After injection, the PEGylated insulin is slowly released at the injection site as the polymer microspheres are broken down by simple hydrolysis. Not only is our technology is unique, but also AB101 does not contain any new excipients and regulatory authorities have already approved numerous products using PEG or biodegradable polymers.

In addition to the proprietary technology for PEGylation of insulin and incorporation of the PEGylated insulin into biodegradable polymers, we have licensed proprietary microparticle manufacturing technology. The microsphere manufacturing process ensures production of a very tight particle size distribution with uniformly small microparticles. This is important to improve manufacturing efficiency and yields as well as to facilitate patient comfort by producing microspheres that can be injected through 25 gauge or smaller needles.

AntriaBio Appoints Two Industry Leaders to its Management Team

Menlo Park, CA - February 19th, 2013 - AntriaBio, Inc. is pleased to announce the appointment, on January 31, 2013, of two new members to its management team: Nevan Elam, AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada, Ph.D, as AntriaBio's Chief Scientific Officer.

Nevan Elam has spent his entire career starting, managing and advising emerging growth companies in key areas of business including finance, marketing and clinical development. Prior to joining AntriaBio, Mr. Elam served as Chief Executive Officer of AeroSurgical Limited, a medical device company based in Europe. Prior to that, he directed the Pulmonary Business Unit of Nektar Therapeutics, which was sold to Novartis in 2008.

Mr. Elam also serves as a managing director of Konus Advisory Group, Inc. ("Konus"), a boutique healthcare consulting and investment firm that specializes in working with U.S. and European healthcare organizations on business opportunities in Asia, Latin America and the Middle East. Mr. Elam holds a J.D. from Harvard University and Bachelor's degree from Howard University.

Sankaram Mantripragada, Ph.D. brings to AntriaBio his strong understanding of the diabetes market and AntriaBio's unique platform technology. From June 2005 until October 2009, Dr. Mantripragada served as Vice President of R&D at PR Pharmaceuticals, Inc. ("PRP"). In January 2013, AntriaBio purchased substantially all of the PRP assets including significant technology, formulation, manufacturing, and intellectual property assets, which together form the basis of AntriaBio's drug development portfolio.

"Dr. Mantripragada's history with PRP's technology and formulation assets and his deep experience in diabetes products and markets make him a clear choice to lead our product development efforts," said Steve Howe, Chairman of AntriaBio. Mr. Howe served as Chairman and Chief Executive Officer of PRP from its formation in 1998 to 2010.

Dr. Mantripragada has been an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He is listed as an inventor on more than 8 patents.

Prior to joining PRP, Dr. Mantripragada served as Director of R&D at Guidant Corporation, now part of Abbott Vascular. Prior to that, he served as Director of R&D and VP of Scientific Development at SkyePharma. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine. Dr. Mantripragada obtained his Ph.D. in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany.